Sentences with phrase «of dabrafenib»

«These new data, demonstrating the impact of nivolumab and of dabrafenib and trametinib on stopping melanoma coming back, show how we might use these drugs earlier in the course of the disease.

She also points out that while the combination of dabrafenib and trametenib earned FDA approval against lung cancer with BRAF V600 mutation in the United States, the combination hasn't yet earned such approval in other countries, and these guidelines are meant to guide care not just in the United States, but internationally.

Researchers have identified characteristics associated with improved outcomes when treating BRAF - mutated advanced melanoma with the combination of dabrafenib and trametinib.

Results from 599 patients receiving combination targeted therapy of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) were:

Not exact matches

Now, a new preclinical study from Penn Medicine researchers found that in many cases the root of the resistance may lie in a never - before - seen autophagy mechanism induced by the BRAF inhibitors vermurafenib and dabrafenib.

In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutations.

The newly FDA - approved therapy, Mekinist (trametinib) in combination with Tafinlar (dabrafenib), is one of the biggest advancements in melanoma treatment in the past 30 years.

Around 40 to 50 per cent of melanoma patients have a faulty BRAF gene and they can be treated with the targeted drugs vemurafenib or dabrafenib.

Two - thirds of the patients are given a combination therapy (dabrafenib and trametinib) prior to surgery.

A phase III trial published last year showed that dabrafenib combined with trametinib in patients with metastatic disease was superior to dabrafenib alone, in terms of progression - free survival (22 % vs 12 % at 3 years; hazard ratio [HR], 0.71) and overall survival (44 % vs 32 % at 3 years; HR, 0.75).